new currency law 2015 Reviews

The T-shaped overpass with the longest and heaviest single span in China successfully turned and crossed Panxi Railway. According to The Paper, on the afternoon of December 11th, after 82 minutes of continuous construction, the T-shaped overpass with the longest and heaviest single span in China turned 52 degrees clockwise from Panxi Railway Vehicle Turning Station to Yangweishao Station under the jurisdiction of Kunming Bureau of China Railway, realizing a "gorgeous turn" and successfully completed the turn across Panxi Railway.Real estate stocks fluctuated lower, with Gorgeous Family, Qixia Construction, Everbright Jiabao and Tiandiyuan falling more than 5%, while urban construction development and Chongqing development followed suit.Guojin Securities: The warm wind of medical policy comes first, then the progress of innovation going out to sea, and then the opportunity of performance reversal. Guojin Securities Research Report said that the core investment opportunities in the pharmaceutical sector in 25 years will revolve around three logics: 1) innovation going out to sea; 2) demand recovery; 3) Policy expectation reversal. At present, the policy warm wind comes first (the medical track policy continues to warm up, and the overall industry expectation is expected to be optimistic); Then, R&D and innovation will go to sea (innovative drug track will continue to make progress, and it will still be the hottest track in the pharmaceutical sector in 2025, especially it is recommended to pay attention to the clinical data reading and commercialization progress of the first-line target, as well as the fluctuation opportunity of the expected difference of the second-line innovative drugs), and then the performance growth rate is expected to bottom out in the first half of 2025 (but it will take time for this improvement in performance growth rate to come. Considering the current industry communication and historical base, it is expected that 4Q24 and 1Q25 should still be cautiously optimistic.)

The total output of automobiles in Shenzhen is expected to exceed 2.8 million vehicles this year. Last year, Shenzhen ranked among the "First City of New Energy Vehicles in China" with an output of 1.733 million vehicles. This year, the total output is expected to exceed 2.8 million vehicles, and it is expected to win the title of "First City of Automobile in China" again. (released by Shenzhen)Shanghai Securities: The pharmaceutical and bio-industry is expected to further repair its performance and valuation. The Shanghai Securities Research Report pointed out that with the support of policies and the adjustment of the internal structure of the industry, the pharmaceutical and bio-industry is expected to further repair its performance and valuation. It is suggested to pay attention to five directions: 1) Innovative drugs (with strong national policy support, the payment terminal is expected to further improve and go to sea to occupy the global market); 2)CXO (the negative impact of the biosafety bill event has been eliminated, and the demand for orders in the superimposed interest rate reduction cycle has increased, which is expected to usher in a double repair of performance and valuation); 3) Imitation and innovation (centralized procurement is expected to clear up, increase innovation, and traditional pharmaceutical companies will usher in new opportunities); 4) Traditional Chinese Medicine (the national policy supports the innovation of traditional Chinese medicine, and its performance is expected to maintain a good growth rate); 5) Medical devices (equipment updating, high-consumption innovation, low-consumption going to sea, etc.). Individual stocks can be concerned about: Baekje Shenzhou, Wuxi PharmaTech, China Resources Sanjiu and so on.Hebai Group: With the help of policy dividends, it will further stimulate new consumer demand and help the company's sales promotion. Hebai Group (000417) said on the interactive platform on December 13th that the company's top 100 electrical appliances actively grasped the new round of "trade-in" policy opportunity, adhered to "policy+activity" to stimulate new consumption potential, and quickly launched more than 33,000 subsidized goods in 8 categories of household appliances and 24 categories of smart homes. Since the implementation of the national subsidy policy in 2024, there have been more than 100,000 rejuvenation machines in stores in Anhui Province, with sales exceeding 400 million yuan, and the sales of household appliances in stores increased by 121% year-on-year. In the next step, the company will seize the time window, continue to integrate resources, closely focus on the national subsidy policy for household appliances in Anhui Province and Hefei consumer vouchers, and further stimulate new consumer demand with the help of policy dividends to help the company's sales increase.

Inter-bank cash bonds are strong as a whole, and national debt and CDB active bonds are down by 3-5bp. The 5-year treasury bonds and CDB active bonds went down by about 5bp, and "24 Treasury bonds with interest 20" reported 1.42%, which was a record low compared with yield to maturity, a Chinese bond in the same period, and "24 CDB 08" reported 1.515% in the same period, a record low since January 26th, 2006. The 10-year "24 interest-bearing treasury bonds 11" initially declined, and now it remains below 1.8%.The application direction of AI fell in early trading, with Jincai Internet falling more than 8%, followed by Tianyu Digital, Huayang Lianzhong, Fushi Holdings, Aofei Entertainment and Fengyuzhu.Shanghai Securities: The pharmaceutical and bio-industry is expected to further repair its performance and valuation. The Shanghai Securities Research Report pointed out that with the support of policies and the adjustment of the internal structure of the industry, the pharmaceutical and bio-industry is expected to further repair its performance and valuation. It is suggested to pay attention to five directions: 1) Innovative drugs (with strong national policy support, the payment terminal is expected to further improve and go to sea to occupy the global market); 2)CXO (the negative impact of the biosafety bill event has been eliminated, and the demand for orders in the superimposed interest rate reduction cycle has increased, which is expected to usher in a double repair of performance and valuation); 3) Imitation and innovation (centralized procurement is expected to clear up, increase innovation, and traditional pharmaceutical companies will usher in new opportunities); 4) Traditional Chinese Medicine (the national policy supports the innovation of traditional Chinese medicine, and its performance is expected to maintain a good growth rate); 5) Medical devices (equipment updating, high-consumption innovation, low-consumption going to sea, etc.). Individual stocks can be concerned about: Baekje Shenzhou, Wuxi PharmaTech, China Resources Sanjiu and so on.